Literature DB >> 16628664

Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma.

Mark Branda1, Jack R Wands.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16628664     DOI： 10.1002/hep.21196

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  46 in total

1.  A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Arihiro Aihara; Chiung-Kuei Huang; Mark J Olsen; Qiushi Lin; Waihong Chung; Qi Tang; Xiaoqun Dong; Jack R Wands
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

2.  Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma.

Authors:  Yoshito Tomimaru; Hironori Koga; Hirohisa Yano; Suzanne de la Monte; Jack R Wands; Miran Kim
Journal:  Liver Int       Date:  2013-05-08       Impact factor: 5.828

3.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 4.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 5.  Systems Challenges of Hepatic Carcinomas: A Review.

Authors:  Dhatri Madduru; Johny Ijaq; Sujata Dhar; Saumyadip Sarkar; Naresh Poondla; Partha S Das; Silvia Vasquez; Prashanth Suravajhala
Journal:  J Clin Exp Hepatol       Date:  2018-05-17

Review 6.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

Review 7.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

8.  Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.

Authors:  Kyu Lim; Chang Han; Yifan Dai; Miaoda Shen; Tong Wu
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

Review 9.  Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken.

Authors:  Dimitrios N Samonakis; George Notas; Nikolaos Christodoulakis; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2008-02-14       Impact factor: 3.199

10.  Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Authors:  T Noda; H Nagano; I Takemasa; S Yoshioka; M Murakami; H Wada; S Kobayashi; S Marubashi; Y Takeda; K Dono; K Umeshita; N Matsuura; K Matsubara; Y Doki; M Mori; M Monden
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.